Invesaro

Stocks Comparison

Abbott Laboratories vs Johnson & Johnson: revenue, profit, margins and growth compared

Abbott Laboratories brought in $44.3B of revenue in fiscal 2025, Johnson & Johnson $94.2B in fiscal 2025. Revenue changed by +5.7% at Abbott Laboratories and +6.0% at Johnson & Johnson on the year before, so Johnson & Johnson grew faster. Abbott Laboratories kept 14.7% of its revenue as net profit, Johnson & Johnson 28.5%. Free cash flow was $7.4B at Abbott Laboratories and $19.7B at Johnson & Johnson.

Side by side, latest fiscal year

ABTJNJ
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 28, 2025)
Revenue$44.3B$94.2B
Revenue growth+5.7%+6.0%
Net income$6.5B$26.8B
Net margin14.7%28.5%
Free cash flow$7.4B$19.7B
Free cash flow margin16.7%20.9%
Earnings per share (diluted)$3.72$11.03
Cash$8.5B$19.7B
Debt$12.9B$41.4B
Price to earnings27.224.6
Market value$175.3B$653.6B
Dividend yield2.37%1.90%
Rank by revenue in sector#18 of 523 · Health care#9 of 523 · Health care

Over the years

Revenue
ABT FY2018: $30.6BABT FY2019: $31.9BABT FY2020: $34.6BABT FY2021: $43.1BABT FY2022: $43.7BABT FY2023: $40.1BABT FY2024: $42BABT FY2025: $44.3BJNJ FY2018: $81.6BJNJ FY2019: $82.1BJNJ FY2020: $82.6BJNJ FY2021: $78.7BJNJ FY2022: $80BJNJ FY2023: $85.2BJNJ FY2024: $88.8BJNJ FY2025: $94.2BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $44.3BJNJ $94.2B
Net income
ABT FY2018: $2.4BABT FY2019: $3.7BABT FY2020: $4.5BABT FY2021: $7.1BABT FY2022: $6.9BABT FY2023: $5.7BABT FY2024: $13.4BABT FY2025: $6.5BJNJ FY2018: $15.3BJNJ FY2019: $15.1BJNJ FY2020: $14.7BJNJ FY2021: $20.9BJNJ FY2022: $17.9BJNJ FY2023: $35.2BJNJ FY2024: $14.1BJNJ FY2025: $26.8BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $6.5BJNJ $26.8B
Net margin
ABT FY2018: 7.7%ABT FY2019: 11.6%ABT FY2020: 13.0%ABT FY2021: 16.4%ABT FY2022: 15.9%ABT FY2023: 14.3%ABT FY2024: 31.9%ABT FY2025: 14.7%JNJ FY2018: 18.8%JNJ FY2019: 18.4%JNJ FY2020: 17.8%JNJ FY2021: 26.5%JNJ FY2022: 22.4%JNJ FY2023: 41.3%JNJ FY2024: 15.8%JNJ FY2025: 28.5%FY18FY19FY20FY21FY22FY23FY24FY25
ABT 14.7%JNJ 28.5%
Revenue growth
ABT FY2019: +4.3%ABT FY2020: +8.5%ABT FY2021: +24.5%ABT FY2022: +1.3%ABT FY2023: -8.1%ABT FY2024: +4.6%ABT FY2025: +5.7%JNJ FY2019: +0.6%JNJ FY2020: +0.6%JNJ FY2021: -4.7%JNJ FY2022: +1.6%JNJ FY2023: +6.5%JNJ FY2024: +4.3%JNJ FY2025: +6.0%FY19FY20FY21FY22FY23FY24FY25
ABT +5.7%JNJ +6.0%
Free cash flow
ABT FY2018: $4.9BABT FY2019: $4.5BABT FY2020: $5.7BABT FY2021: $8.6BABT FY2022: $7.8BABT FY2023: $5.1BABT FY2024: $6.4BABT FY2025: $7.4BJNJ FY2018: $18.5BJNJ FY2019: $19.9BJNJ FY2020: $20.2BJNJ FY2021: $19.8BJNJ FY2022: $17.2BJNJ FY2023: $18.2BJNJ FY2024: $19.8BJNJ FY2025: $19.7BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $7.4BJNJ $19.7B

Fiscal years as each company reports them; the two may end in different months.

Questions about Abbott Laboratories and Johnson & Johnson

Which is bigger by revenue, Abbott Laboratories or Johnson & Johnson?

Johnson & Johnson is bigger by revenue: $94.2B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.

Which keeps more of its revenue as profit, Abbott Laboratories or Johnson & Johnson?

Abbott Laboratories had a net margin of 14.7% in fiscal 2025; Johnson & Johnson had 28.5% in fiscal 2025.

Which grew revenue faster, Abbott Laboratories or Johnson & Johnson?

In their latest fiscal years revenue changed by +5.7% at Abbott Laboratories and +6.0% at Johnson & Johnson.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies